Ultragenyx Q2 FY26 net loss narrows to $92 million; revenue rises to $214 million

Reuters2026/08/04 20:31

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Ultragenyx Q2 revenue rose 28.14% to $214 million; net loss narrowed to $92 million from $115 million.
Crysvita revenue increased to $156 million from $121 million; Dojolvi revenue climbed to $27 million from $23 million.
Operating expenses grew to $289 million from $275 million; cash, cash equivalents, and marketable securities totaled $436 million at June 30.
Reaffirmed 2026 revenue guidance of $730 million-$760 million, excluding potential new launches; targets profitability in 2027.
FDA set PDUFA dates for DTX401 on Aug. 23, 2026, and UX111 on Sept. 19, 2026; Phase 3 Aspire data for GTX-102 expected in September or October.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ultragenyx Pharmaceutical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608041605PRIMZONEFULLFEED9803616) on August 04, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Ultragenyx Q2 FY26 net loss narrows to $92 million; revenue rises to $214 million

You may also like

Crypto prices